<DOC>
	<DOCNO>NCT00135135</DOCNO>
	<brief_summary>This phase II window study combination ZD1839 ( gefitinib ) irinotecan child high-risk neuroblastoma follow standard induction chemotherapy , intensification autologous stem cell transplantation , oral maintenance phase 13-cis-retinoic acid topotecan . We hypothesize ZD1839 ( gefitinib ) irinotecan window efficacious .</brief_summary>
	<brief_title>Therapy Children With Neuroblastoma</brief_title>
	<detailed_description>The study five part phase . In first part combination irinotecan gefitinib study . After , patient respond well surgery remove tumor . This follow third part include nine month treatment cisplatin , adriamycin , etoposide , cyclophosphamide , topotecan . The fourth part intensification melphalan , etoposide carboplatin blood stem cell rescue . During part , radiation also give site disease . Finally , monthly treatment oral retinoic acid , alternate oral topotecan , continue total 16 month maintenance . It anticipate take 2 year complete entire treatment plan . This study multiple therapeutic , pharmacologic , biologic , diagnostic image objective : - To estimate whether oral gefitinib two course intravenous irinotecan decrease incidence fever/neutropenia , duration hospitalization , duration intravenous antibiotic number platelet RBC transfusion first six week treatment compare topotecan window NB97 . - To estimate local control primary site disease treatment plan . - To estimate overall survival progression-free survival patient treat approach . - To estimate feasibility resect primary tumor two course irinotecan gefitinib . - To evaluate disposition irinotecan gefitinib previously untreated patient neuroblastoma . - To evaluate disposition intravenous oral topotecan previously untreated patient neuroblastoma . - To evaluate pharmacogenetic determinant gefitinib irinotecan pharmacokinetics pharmacodynamics ( e.g. , CYP3A4/5 , UGT1A1 , ABCG2 ( BCRP ) polymorphism ) . - To evaluate pharmacogenetic determinant topotecan pharmacokinetics pharmacodynamics ( e.g. , CYP3A4/5 ABC transporter polymorphism ) . - To evaluate tumor sample molecular cellular expression EGFR , MRP4 ABCG2 ( BCRP ) utilize appropriate laboratory technique . - To describe relative frequency positive bone marrow sensitive MRD method diagnosis , window therapy , time stem cell harvest , several time point follow completion intensification . These result compare timing pattern disease recurrence . - To describe percentage primary metastatic neuroblastoma amplify ICAM-2 chromosome 17 . - To generate preliminary data regard potential use ICAM-2 copy number prognostic indicator neuroblastoma . - To determine level angiogenic factor VEGF bFGF peripheral circulation patient diagnosis , window therapy , time stem cell harvest several time point follow completion intensification . These result compare degree tumor response time disease recurrence . - To procure tumor sample construction tissue microarray block utilized biologic characterization tumor . - To prospectively evaluate FDG PET image marker disease diagnosis , ( pre post window therapy ) , prior intensification , completion therapy . - To generate preliminary data use contrast enhance ultrasound magnetic resonance image evaluate change tumor vascularity various timepoints therapy . Details Treatment Interventions : Window Phase Irinotecan 15mg/m2 daily x 5 day two week daily oral gefitinib 112.5 mg/m2 daily x 12 days. , follow 9 day rest , course repeat . Subjects respond window therapy receive course instead topotecan Block 2 , course 6 ( week 21 ) induction . Induction Therapy ( follow window ) : Cyclophosphamide 1.5 gm/m2 daily x 2 I.V . day 1 &amp; 2 Adriamycin 50 mg/m2 I.V . day 1 MESNA : 375 mg/m2 I.V . immediately follow cyclophosphamide 3 6 hour post-infusion . Etoposide : 30 mg/m2 30 minute , follow etoposide 250 mg/m2/day x 3 day I.V . continuous infusion ( day 2-5 ) , give induction therapy course 1 , 4 , 7 . Cisplatin 40 mg/m2/day x 5 I.V . 1 hour ( day 1-5 ) Etoposide 200 mg/m2/day x 3 I.V . 1 hour ( day 2 , 3 , 4 ) , give induction course 2 , 5 , 8 . IV topotecan adjust AUC 100 Â± 20nghr/ml daily x 5 day two week , course 3 , 6 ( patient respond window ) , 9 induction . Intensification : Melphalan , Etopophos carboplatin : Day -8 , -7 , -6 , -5 : Melphalan 45 mg/m2 IV Day -4 : Etopophos 40 mg/kg/day IV Day -4 , -3 , &amp; -2 : Carboplatin ( AUC target 4.1 ) Day 0- infusion peripheral blood stem cell previously harvest pheresis . Maintenance : 13 cis-retinoic acid oral topotecan courses:13-cis-retinoic acid 160 mg/m2/day divide two equal dos give orally BID x 14 day , follow 14 day rest . This repeat x one . Subjects less equal 12 kg give 5.33 mg/kg/day divide BID . These course alternate 2 month oral topotecan daily 5 day 2 consecutive week 1.8 mg/m2/day , 0.06 mg/kg/day patient less 12 month old ( total 10 dos ) total 16 course ( four , two-month course ) . Radiation therapy : Radiation therapy primary metastatic disease site follow peripheral blood stem cell transplant exception patient require emergent radiation . External beam radiotherapy deliver primary site select metastatic site . Radiotherapy plan initiate four week follow stem cell reinfusion . Surgery : After recovery induction re-evaluation tumor status , subject undergo surgery resection primary tumor mass careful lymph node staging , surgery possible irinotecan ZD1839 window . Peripheral blood stem cell collection infusion : After course 3 , subject undergo peripheral blood stem cell ( PBSC ) harvest . If unsuccessful , harvest do subsequent chemotherapy course . Subjects mobilize filgrastim ( 10mcg/kg/day ) . PBSC harvest perform leukapheresis possible , bone marrow harvest . Stem cell store re-infused intensification chemotherapy .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Patient le equal 18 year age Patient newly diagnose highrisk neuroblastoma Patient adequate kidney liver function No prior therapy , unless emergency situation require local tumor treatment ( discuss PI ) Known severe hypersensitivity ZD1839 excipients product Any evidence , judge investigator , severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) Evidence significant clinical disorder laboratory find make undesirable subject participate trial . Pregnant breast feeding ( woman childbearing potential ) . Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St. John 's Wort . Treatment nonapproved investigational drug within 30 day Day 1 study treatment . Any evidence clinically active interstitial lung disease ( patient chronic stable radiographic change asymptomatic need exclude ) . Children INSS 4 disease , age &lt; 12 month 3 favorable biologic feature ( nonamplified MYCN , favorable pathology DNA index</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Childhood Tumor</keyword>
	<keyword>Neoplasms</keyword>
</DOC>